ESMO 2017: News Articles

Interested in what happened during the ESMO 2017 Congress?

Read our news articles here

Date Title Topic
09 Sep 2017 ESMO 2017: Promising Response Rates in Patients with Metastatic TNBC Treated with Nivolumab After Induction Treatment Breast cancer - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Promising Results Demonstrated with DCC-2618 in GIST Sarcomas - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: TIL Levels Signal Pembrolizumab Response in Metastatic TNBC Breast cancer - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status Gynaecologic malignancies - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Progression-free Rate Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients with Synchronous mRCC Genitourinary cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Patients with Platinum Sensitive Ovarian Cancer Maintan QoL During Maintenance Niraparib Therapy Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: PD-L1 as a Prognostic Factor in Patients with Glioblastoma Central nervous system malignancies - Pathology/Molecular biology
08 Sep 2017 ESMO 2017: Combined Nivolumab and Radiotherapy ± Temozolomide Is Safe in Patients With Newly Diagnosed Glioblastoma Central nervous system malignancies - Cancer Immunology and Immunotherapy
08 Sep 2017 ESMO 2017: Germline Mutations in DNA Repair Genes Lowers Survival in mCRPC Genitourinary cancers - Translational research
08 Sep 2017 ESMO 2017: Significant Clinical Activity Demonstrated with 177Lu-PSMA617 in mCRPC Genitourinary cancers
08 Sep 2017 ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy Gastrointestinal cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Combined Letrozole plus Palbociclib is not Better than Chemotherapy as Neoadjuvant Treatment in Luminal Breast Cancer Breast cancer - Anticancer agents & Biologic therapy